Our unique ability to repeatedly and consistently translate science into medicine has led to a robust pipeline of clinical-stage medicines, all of which were discovered in our laboratories. Our investigational treatments target allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.

            Interact with the Regeneron Pipeline

            Select Therapeutic Area(s):
            Select Phase(s):
            Select Collaborator(s):

            Displaying item(s)

            Clear Filters

            Regeneron Pipeline: Phase 1 Medicines Regeneron Pipeline: Phase 1 Medicines
            • REGN-COV2
              SARS-CoV-2 Antibodies Treatment for hospitalized patients and non-hospitalized patients with COVID-19
            • CEMIPLIMAB*
              PD-1 Antibody Cancer
            • REGN3767
              LAG-3 Antibody Solid tumors, advanced hematologic malignancies
            • REGN1979
              CD20 X CD3 Antibody B-cell malignancies
            • REGN4018*
              MUC16 X CD3 Antibody Platinum-resistant ovarian cancer
            • REGN5458*
              BCMA X CD3 Antibody Multiple myeloma
            • REGN5459*
              BCMA X CD3 Antibody Multiple myeloma
            • REGN5678
              PSMA X CD28 Antibody Prostate cancer
            • REGN5093
              MET X MET Antibody MET-altered advanced non-small cell lung cancer (NSCLC)
            • REGN5713-5714-5715
              Bet v 1 Antibodies Birch Allergy
            Regeneron Pipeline: Phase 2 Medicines Regeneron Pipeline: Phase 2 Medicines
            • AFLIBERCEPT
              VEGF-Trap High-dose (8mg) for wet age-related macular degeneration (AMD)
            • CEMIPLIMAB*
              PD-1 Antibody Basal cell carcinoma (BCC), metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), neoadjuvant CSCC
            • REGN1979
              CD20 X CD3 Antibody B-cell non-Hodgkin lymphoma
            • SARILUMAB*
              IL-6R Antibody Polyarticular-course juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis
            • DUPILUMAB*
              IL-4R Antibody Grass allergy, peanut allergy
            • REGN1908-1909
              Fel d 1 Antibodies Cat allergy
            • REGN3500*
              IL-33 Antibody Asthma, chronic obstructive pulmonary disease (COPD)
            • REGN5069
              GFRα3 Antibody Osteoarthritis pain of the knee
            • GARETOSMAB
              Activin A Antibody Fibrodysplasia Ossificans Progressiva (FOP)
            • EVINACUMAB
              ANGPTL-3 Antibody Refractory hypercholesterolemia (both HeFH and non-FH), severe hypertriglyceridemia
            • POZELIMAB
              C5 Antibody Paroxysmal nocturnal hemoglobinuria, CD-55 deficient protein-losing enteropathy
            • REGN4461
              LEPR Antibody Generalized lipodystrophy
            Regeneron Pipeline: Phase 3 Medicines Regeneron Pipeline: Phase 3 Medicines
            • AFLIBERCEPT
              VEGF-Trap Retinopathy of prematurity (ROP)
            • CEMIPLIMAB*
              PD-1 Antibody non-small cell lung cancer (NSCLC), cervical cancer, adjuvant cutaneous squamous cell carcinoma (CSCC)
            • ALIROCUMAB
              PCSK9 Antibody Homozygous familial hypercholesterolemia (HoFH) in adults and pediatric patients, heterozygous familial hypercholesterolemia in pediatric patients
            • EVINACUMAB
              ANGPTL-3 Antibody Homozygous familial hypercholesterolemia (HoFH)
            • DUPILUMAB*
              IL-4R Antibody Atopic dermatitis in pediatric patients 6 mo.–11 y.o., asthma in pediatric patients 6-11 y.o., eosinophilic esophagitis, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, prurigo nodularis, chronic spontaneous urticaria
            • SARILUMAB*
              IL-6R Antibody Hospitalized "critical" COVID-19 patients, polymyalgia rheumatica, giant cell arteritis
            • REGN-EB3
              Ebola Virus Antibodies Ebola virus infection
            • FASINUMAB?
              NGF Antibody Osteoarthritis pain of the knee or hip

            No results found, please adjust your filter selection and try again.

            * In collaboration with Sanofi

            ? In collaboration with Teva and Mitsubishi Tanabe

            This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.